{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:03:52Z","timestamp":1791353032407,"version":"4.3.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.autrev.2014.08.018","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T04:15:46Z","timestamp":1409112946000},"page":"1182-1188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review"],"prefix":"10.1016","volume":"13","author":[{"given":"Maria Giovanna","family":"Danieli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Pedini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Logullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.autrev.2014.08.018_bb0005","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.autrev.2014.08.018_bb0010","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulinin treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2014.08.018_bb0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2249.2012.04594.x","article-title":"Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy","volume":"169","author":"Orange","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"10.1016\/j.autrev.2014.08.018_bb0020","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2014.08.018_bb0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/cei.12195","article-title":"Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies","volume":"175","author":"Melzer","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"4\u20135","key":"10.1016\/j.autrev.2014.08.018_bb0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.autrev.2014.01.026","article-title":"Diagnosis and classification of immune-mediated thrombocytopenia","volume":"13","author":"Lo","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2014.08.018_bb0035","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.autrev.2013.01.002","article-title":"A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro\/La-related congenital atrioventricular block. A case series and review of the literature","volume":"12","author":"Ruffatti","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.autrev.2014.08.018_bb0040","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.autrev.2014.08.018_bb0045","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2014.08.018_bb0050","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.autrev.2012.10.015","article-title":"Complex regional pain syndrome, prototype of a novel kind of autoimmune disease","volume":"12","author":"Goebel","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2014.08.018_bb0055","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/art.37815","article-title":"Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1\/Th2 cytokine profiles in patients with Kawasaki disease","volume":"65","author":"Wang","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2014.08.018_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.autrev.2012.04.006","article-title":"Intravenous immunoglobulin for the treatment of Crohn's disease","volume":"12","author":"Rogosnitzky","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.018_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001797.pub2","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"1","author":"Eftimov","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2014.08.018_bb0070","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004429.pub2","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","volume":"2","author":"van Schaik","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.08.018_bb0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2249.2009.04025.x","article-title":"Clinical applications of intravenous immunoglobulins in neurology","volume":"158","author":"Hughes","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0080","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2014.08.018_bb0085","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/cei.12194","article-title":"Diagnosis, pathogenesis and treatment of myositis: recent advances","volume":"175","author":"Carstens","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2014.08.018_bb0090","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.autrev.2013.01.003","article-title":"The future of immunoglobulin therapy: an overview of the 2nd international workshop on natural antibodies in health and disease","volume":"12","author":"Miescher","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.08.018_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","article-title":"Subcutaneous immunoglobulin: opportunities and outlook","volume":"158","author":"Misbah","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0100","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/jnnp-2013-305644","article-title":"Subcutaneous immunoglobulin therapy for inflammatory neuropathy: current evidence base and future prospects","volume":"85","author":"Rajabally","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2014.08.018_bb0105","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 2","key":"10.1016\/j.autrev.2014.08.018_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2011.04387.x","article-title":"Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy","volume":"164","author":"Kaveri","year":"2011","journal-title":"Clin Exp Immunol"},{"issue":"29","key":"10.1016\/j.autrev.2014.08.018_bb0115","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.2174\/138161211798157540","article-title":"Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases","volume":"17","author":"Katz","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.autrev.2014.08.018_bb0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","article-title":"What is the contents of the magic draft IVIg?","volume":"7","author":"Seite","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2014.08.018_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/imt.13.146","article-title":"Subcutaneous IgG in neurologic diseases","volume":"6","author":"Berger","year":"2014","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.autrev.2014.08.018_bb0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.autrev.2012.08.017","article-title":"Tregitope update: mechanism of action parallels IVIg","volume":"12","author":"Cousens","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2014.08.018_bb0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2009.04028.x","article-title":"6th International Immunoglobulin Symposium: poster presentations","volume":"158","author":"Fernandez-Cruz","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.autrev.2011.08.004","article-title":"B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells","volume":"11","author":"Maddur","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2014.08.018_bb0145","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar4512","article-title":"Roles of mast cells in the pathogenesis of inflammatory myopathy","volume":"17;16","author":"Yokota","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2014.08.018_bb0150","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/978-1-62703-586-6_18","article-title":"Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases","volume":"1060","author":"Blank","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0155","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0160","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2012-11-468264","article-title":"Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells","volume":"122","author":"Trinath","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2014.08.018_bb0165","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2353\/ajpath.2009.080422","article-title":"Role of regulatory T cells in a new mouse model of experimental autoimmune myositis","volume":"174","author":"Allenbach","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0170","first-page":"293","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: revisiting the role of intravenous immmunoglobulins","volume":"15","author":"Chapman","year":"2013","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.autrev.2014.08.018_bb0175","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/brain\/awf070","article-title":"Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10","volume":"125","author":"Kieseier","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2014.08.018_bb0180","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","article-title":"Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients","volume":"47","author":"Yan","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0190","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nri3401-c1","article-title":"IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist","volume":"14","author":"von Gunten","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0195","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awh127","article-title":"Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies","volume":"127","author":"Zhang","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2014.08.018_bb0200","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1212\/WNL.0b013e3181bd1139","article-title":"Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP","volume":"73","author":"Iijima","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2014.08.018_bb0205","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2014.08.018_bb0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","article-title":"Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis","volume":"33","author":"Danieli","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0215","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10067-008-0892-2","article-title":"Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis?","volume":"27","author":"Schleinitz","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0220","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mus.23895","article-title":"Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia","volume":"48","author":"Pars","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2014.08.018_bb0225","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0230","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jns5.12017","article-title":"Efficacy and safety of Privigen(\u00ae) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)","volume":"18","author":"L\u00e9ger","year":"2013","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2014.08.018_bb0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0240","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/ene.12080","article-title":"Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"20","author":"Markvardsen","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0245","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2014.08.018_bb0250","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1529-8027.2011.00340.x","article-title":"The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin","volume":"16","author":"Cocito","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2014.08.018_bb0255","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00415-006-0258-0","article-title":"Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies","volume":"253","author":"K\u00f6ller","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2014.08.018_bb0260","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1529-8027.2011.00330.x","article-title":"A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study","volume":"16","author":"Misbah","year":"2011","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2014.08.018_bb0265","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1529-8027.2009.00218.x","article-title":"Subcutaneous immunoglobulin therapy for multifocal motor neuropathy","volume":"14","author":"Eftimov","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.autrev.2014.08.018_bb0270","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1468-1331.2009.02568.x","article-title":"Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial","volume":"16","author":"Harbo","year":"2009","journal-title":"Eur J Neurol"},{"issue":"15","key":"10.1016\/j.autrev.2014.08.018_bb0275","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1212\/WNL.0b013e3181f735ce","article-title":"Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy","volume":"75","author":"Harbo","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.autrev.2014.08.018_bb0285","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10072-010-0352-z","article-title":"Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report","volume":"31","author":"Dacci","year":"2010","journal-title":"Neurol Sci"},{"issue":"1\u20132","key":"10.1016\/j.autrev.2014.08.018_bb0290","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2012.09.033","article-title":"Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions","volume":"324","author":"Bayas","year":"2013","journal-title":"J Neurol Sci"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214001621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T17:11:51Z","timestamp":1650042711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214001621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1568997214001621"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.018","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2014.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}